Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

We recently compiled a list of 11 Best Undervalued Stocks to Invest in Now. Lincoln National Corporation stands third on our ...

Backed by Bain Capital LP, the company has invited investment banks to pitch for roles in arranging the share sale, the ...

UnitedHealth Group Inc. appointed Wayne DeVeydt to become chief financial officer, replacing longtime finance chief John Rex.

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Lincoln National (LNC) posts strong Q2 2025 results with 32% YoY income growth, record group margins, and strategic capital deployment initiatives.

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...